Objective:
To evaluate the impact of OTX-TKI on macular fluid metrics in patients with nonproliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (CI-DME).
Key Findings:
- OTX-TKI-treated eyes showed greater reductions in mean retinal-RPE volume (0.92 mm³ vs 0.16 mm³ in sham).
- Central subfield thickness decreased by 15.4 µm in OTX-TKI group, while it increased by 4.7 µm in sham.
- Intraretinal fluid volume decreased in OTX-TKI group but increased in sham.
Interpretation:
The results indicate that OTX-TKI may provide a sustained therapeutic effect, reducing retinal fluid and potentially slowing NPDR progression.
Limitations:
- Small sample size (21 eyes).
- Further data needed to confirm findings.
Conclusion:
OTX-TKI shows promise as a long-acting treatment for NPDR, warranting further investigation.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.